Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric heart failure study of LCZ696 versus enalapril
MOH_2017-11-30_000683Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) comparing Entresto with enalapril (2 arms). Primary endpoint: Primary efficacy objective. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
sacubitril + valsartanenalapril
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on MOH_2017-11-30_000683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-30_000683.